MA45695A - Protéines de liaison à un antigène qui se lient à cxcr3 - Google Patents
Protéines de liaison à un antigène qui se lient à cxcr3Info
- Publication number
- MA45695A MA45695A MA045695A MA45695A MA45695A MA 45695 A MA45695 A MA 45695A MA 045695 A MA045695 A MA 045695A MA 45695 A MA45695 A MA 45695A MA 45695 A MA45695 A MA 45695A
- Authority
- MA
- Morocco
- Prior art keywords
- bind proteins
- cxcr3
- antigen
- cxcr3 antigen
- bind
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462041020P | 2014-08-22 | 2014-08-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA45695A true MA45695A (fr) | 2019-05-22 |
Family
ID=55347733
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA045695A MA45695A (fr) | 2014-08-22 | 2015-08-07 | Protéines de liaison à un antigène qui se lient à cxcr3 |
MA040526A MA40526A (fr) | 2014-08-22 | 2015-08-07 | Protéines de fixation antigénique fixant le cxcr3 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040526A MA40526A (fr) | 2014-08-22 | 2015-08-07 | Protéines de fixation antigénique fixant le cxcr3 |
Country Status (16)
Country | Link |
---|---|
US (3) | US9765145B2 (fr) |
EP (2) | EP3183000A4 (fr) |
JP (1) | JP2017529331A (fr) |
KR (1) | KR20170067729A (fr) |
CN (1) | CN107148282A (fr) |
AU (1) | AU2015305894A1 (fr) |
BR (1) | BR112017003487A2 (fr) |
CA (1) | CA2958673A1 (fr) |
EA (1) | EA201790437A1 (fr) |
IL (1) | IL250629A0 (fr) |
MA (2) | MA45695A (fr) |
MX (1) | MX2017002380A (fr) |
PH (1) | PH12017500332A1 (fr) |
SG (1) | SG11201701382PA (fr) |
WO (1) | WO2016028523A2 (fr) |
ZA (1) | ZA201701941B (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201840585A (zh) * | 2016-12-22 | 2018-11-16 | 法商賽諾菲公司 | 用於白斑病的治療的抗人cxcr3抗體 |
KR20190095943A (ko) * | 2016-12-22 | 2019-08-16 | 사노피 | 고갈 활성을 갖는 인간화 cxcr3 항체 및 이의 사용 방법 |
AU2022218137A1 (en) | 2021-02-03 | 2023-08-24 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
CN113684238A (zh) * | 2021-08-09 | 2021-11-23 | 广州医科大学附属第一医院(广州呼吸中心) | Cxc趋化因子受体3作为咳嗽药物靶点的用途 |
WO2023076876A1 (fr) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation de réponses immunitaires à des vecteurs viraux |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0206448B1 (fr) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hémoglobine liée à un poly(oxyde d'alkylène) |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
WO1994001451A2 (fr) | 1992-07-13 | 1994-01-20 | Bionebraska, Inc. | Procede pour la modification de polypeptides recombines |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
CA2146559A1 (fr) | 1992-10-23 | 1994-05-11 | Melanie K. Spriggs | Methodes pour preparer des proteines oligomeres solubles |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
WO2000009560A2 (fr) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Production de molecules modifiees avec demi-vie serique prolongee |
GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
US6938003B2 (en) | 2000-06-30 | 2005-08-30 | Mahesh Harpale | Method and apparatus for a credibility reporting system to augment an online exchange |
AU2001296962A1 (en) | 2000-09-29 | 2002-04-08 | Schering Corporation | Pegylated interleukin-10 |
GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
WO2005030793A2 (fr) * | 2003-09-24 | 2005-04-07 | Millennium Pharmaceuticals, Inc. | Anticorps se liant aux cxcr3 humains |
CN101796073B (zh) * | 2007-02-01 | 2014-08-13 | 特瓦生物制药美国有限公司 | 针对cxcr3的人源化抗体 |
JP5498566B2 (ja) | 2009-03-20 | 2014-05-21 | アムジェン インコーポレイテッド | アルファ−4−ベータ−7ヘテロ二量体特異的アンタゴニスト抗体 |
ES2698606T3 (es) * | 2012-01-20 | 2019-02-05 | Genzyme Corp | Anticuerpos anti-CXCR3 |
-
2015
- 2015-08-07 EP EP15833176.9A patent/EP3183000A4/fr not_active Withdrawn
- 2015-08-07 MA MA045695A patent/MA45695A/fr unknown
- 2015-08-07 JP JP2017510556A patent/JP2017529331A/ja not_active Withdrawn
- 2015-08-07 EP EP18201628.7A patent/EP3485910A2/fr not_active Withdrawn
- 2015-08-07 EA EA201790437A patent/EA201790437A1/ru unknown
- 2015-08-07 MX MX2017002380A patent/MX2017002380A/es unknown
- 2015-08-07 WO PCT/US2015/044348 patent/WO2016028523A2/fr active Application Filing
- 2015-08-07 US US14/821,559 patent/US9765145B2/en active Active
- 2015-08-07 BR BR112017003487A patent/BR112017003487A2/pt not_active Application Discontinuation
- 2015-08-07 AU AU2015305894A patent/AU2015305894A1/en not_active Abandoned
- 2015-08-07 MA MA040526A patent/MA40526A/fr unknown
- 2015-08-07 CA CA2958673A patent/CA2958673A1/fr not_active Abandoned
- 2015-08-07 CN CN201580056545.7A patent/CN107148282A/zh not_active Withdrawn
- 2015-08-07 SG SG11201701382PA patent/SG11201701382PA/en unknown
- 2015-08-07 KR KR1020177007935A patent/KR20170067729A/ko unknown
-
2017
- 2017-02-15 IL IL250629A patent/IL250629A0/en unknown
- 2017-02-22 PH PH12017500332A patent/PH12017500332A1/en unknown
- 2017-03-20 ZA ZA2017/01941A patent/ZA201701941B/en unknown
- 2017-08-21 US US15/682,206 patent/US20190008955A1/en active Pending
-
2018
- 2018-10-09 US US16/155,278 patent/US10668148B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2015305894A1 (en) | 2017-04-06 |
WO2016028523A3 (fr) | 2016-08-04 |
CA2958673A1 (fr) | 2016-02-25 |
US9765145B2 (en) | 2017-09-19 |
IL250629A0 (en) | 2017-04-30 |
JP2017529331A (ja) | 2017-10-05 |
BR112017003487A2 (pt) | 2017-11-28 |
EP3183000A2 (fr) | 2017-06-28 |
PH12017500332A1 (en) | 2017-07-17 |
SG11201701382PA (en) | 2017-03-30 |
US10668148B2 (en) | 2020-06-02 |
US20190008955A1 (en) | 2019-01-10 |
ZA201701941B (en) | 2018-05-30 |
EA201790437A1 (ru) | 2017-08-31 |
WO2016028523A8 (fr) | 2016-09-15 |
MA40526A (fr) | 2017-06-28 |
US20160053013A1 (en) | 2016-02-25 |
WO2016028523A2 (fr) | 2016-02-25 |
US20190060448A1 (en) | 2019-02-28 |
KR20170067729A (ko) | 2017-06-16 |
CN107148282A (zh) | 2017-09-08 |
MX2017002380A (es) | 2017-09-15 |
EP3183000A4 (fr) | 2018-04-25 |
EP3485910A2 (fr) | 2019-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
DK3344654T3 (da) | Anti-lag-3-antistoffer | |
DK3455257T3 (da) | Anti-pd-l1-antistoffer | |
DK3332006T5 (da) | Hidtil ukendte anti-PD-L1-antistoffer | |
DK3292141T3 (da) | Fusionsproteiner | |
DK3197453T3 (da) | Kimært protein | |
DK3180363T3 (da) | Sirp-alpha-immunoglobulin fusionsproteiner | |
DK4089113T3 (da) | Polypeptider | |
KR20180085002A (ko) | 인간화된 항-cll-1 항체 | |
DK3350218T3 (da) | Polyomavirus-neutraliserende antistoffer | |
DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
DK3107562T3 (da) | P97-ids-fusionsproteiner | |
DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
MA53887A (fr) | Anticorps à liaison protofibrille a-bêta améliorée | |
FR3042250B1 (fr) | Joint a section constante | |
FI20155191A (fi) | Nivel | |
DK3164410T3 (da) | Protein-indvinding | |
CL2016002136A1 (es) | Proteinas de fusión uti | |
DK3484921T3 (da) | Anti-IL-22R antistoffer | |
MA45695A (fr) | Protéines de liaison à un antigène qui se lient à cxcr3 | |
DK3795591T3 (da) | Cys80-konjugerede immunoglobuliner | |
ITUB20155097A1 (it) | Anticorpi umanizzati anti-BAG3 | |
IT201700072559A1 (it) | Interfaccia aptica | |
DK3271724T3 (da) | Anvendelse af en standard til påvisning af proteinaggregater i en proteinfejlfoldningssygdom | |
DK3448420T3 (da) | Anti-notch3-antistof |